Side-by-side financials for APVO and LLY. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | APVO | LLY |
|---|---|---|
| Market cap | - | $1.072 T |
| US-listed rank | - | #10 |
| Revenue (latest FY) | $3.11M | $65.18B |
| Net income (latest FY) | -$25.97M | $20.64B |
| Net margin | -833.9% | 31.7% |
| P/E (trailing FY) | - | 51.9 |
| SEC filings | 690 | 989 |
In their latest fiscal years, Aptevo Therapeutics Inc. reported $3.11M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Aptevo Therapeutics Inc. and ELI LILLY & Co, or browse the full rankings.